Objective. To evaluate if new imiquimod formulations using a shorter treatment duration are
safe and efficacious to treat anogenital warts. Methods. In two studies 534 women≥ 12 …

Objective: To investigate the efficacy and safety of imiquimod 5% cream in the treatment of
anogenital warts in a female population. Methods: In two open-label studies, female patients …

Objective: The objective of this randomized, double-blind, placebo-controlled trial was to
evaluate the mechanism of action of imiquimod cream in the treatment of anogenital warts …

The complete treatment of anogenital warts has not been obtained with any combination of
methods; therefore, new methods are still under investigation. In this study the activity and …

Imiquimod 5% cream (Aldara, Graceway Pharmaceuticals) is an immune response modifier
used for the topical treatment of anogenital warts in non-HIV-infected patients. Several …

The purpose of this study was to assess the first-line therapeutic performance of imiquimod
5% cream in 17 pregnant women with external anogenital warts. The mean size of total wart …

Our objective was to determine the efficacy and safety of imiquimod 5% cream in the
treatment of external genital/perianal warts in an open-label Phase IIIB trial. Patients applied …

Introduction Cutaneous warts are highly prevalent lesions caused by the infection of
keratinocytes by different types of human papillomaviruses. Although cutaneous warts are …

Cytodestructive or surgical therapy for patients with anogenital warts is frequently associated
with recurrence. In February 1997, the US Food and Drug Administration approved …

This study aims to evaluate the effectiveness of imiquimod treatment of external anogenital
warts and analyse its possible relationship with patient treatment satisfaction and …